MAYO CLINIC

Berlin-based Aignostics GmbH, a spin-out from Charité and Mayo Clinic, raised $34m in Series B funding led by Athos and HTGF, bringing total funds to $55m. The AI image analysis specialist plans to expand its digital pathology offerings for target and companion diagnostics, leveraging its RudolfV foundation model. Aignostics aims to grow in the US and collaborate with Mayo Clinic for novel data-driven models and biopharma products.

Stephen M. Ansell discusses integrating immunotherapy like nivolumab/AVD into advanced Hodgkin lymphoma treatment, emphasizing personalized care based on patient tolerance, particularly in elderly patients.

Aignostics raises $34M in Series B funding to advance AI-powered pathology and precision medicine, with plans to develop new products, expand in the US, and collaborate with Mayo Clinic on advanced foundation models.

Max Healthcare and Mayo Clinic co-hosted 'Cardiology Summa2024', a summit discussing latest cardiology advancements, including AI in diagnostics. Dr Balbir Singh highlighted AI's potential in early disease detection and personalized treatment, aiming to elevate India's cardiac care globally. Dr Gurpreet Sandhu emphasized Mayo Clinic's patient-centric approach and the collaboration's goal to strengthen global cardiovascular health.

Dr. Nir Barzilai predicts impactful gerotherapeutics will take decades to reach the average person. Successful gerotherapy must target aging hallmarks, extend health span, undergo extensive clinical trials, and influence all-cause mortality. Four FDA-approved drugs show promise: GLP-1s, SGLT2 inhibitors, bisphosphonates, and metformin. Despite their potential, these drugs are not approved for anti-aging alone and are intended for those with pre-existing conditions. Lifestyle changes remain crucial for healthy aging.

Aignostics raises $34 million in Series B financing to support new product offerings, US expansion, and pathology foundation model development with Mayo Clinic.

Harvard Apparatus Regenerative Technology partners with Capital Institute of Pediatrics to develop treatments for Esophageal Atresia using the Cellspan Esophageal Implant (CEI). The collaboration aims to improve patient outcomes through clinical research and product development, focusing on conducting Investigator initiated trials to evaluate CEI's safety and efficacy.

EVOLVED study shows early aortic valve replacement (AVR) with TAVI or surgery does not lower mortality risk in asymptomatic patients with myocardial fibrosis. However, it reduces unplanned aortic stenosis-related hospitalizations. Investigators suggest early intervention improves quality of life by keeping patients out of the hospital, despite not extending life.

Harvard Apparatus Regenerative Technology partners with Capital Institute of Pediatrics to develop treatments for Esophageal Atresia using the Cellspan Esophageal Implant.